Patients vaccinated between lymphoma treatment initiation and one year after its completion showed a poor antibody response but preserved CD4 and CD8 T cell responses, contrasting with a preserved B cell vaccinal response when vaccination was completed before the treatment initiation. This evidence concerns the gene CD4 and lymphoma.